DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Newsmart
  • Private Markets
  • Risk & Compliance
  • WSJ.com
  • WSJ Conference
  • WSJ Pro
  • WSJ Video
NEWS CORP
  • Big Decisions
  • Business Spectator
  • Checkout51
  • Harper Collins
  • New York Post
  • PropTiger
  • REA
  • realtor.com
  • Storyful
  • The Australian
  • The Sun
  • The Times
Stoxx 600 ▲
339.48 0.80%
  Nikkei ▲
16878.96 -1.31%
  U.S. 10 Yr ▲
-3/32 yield 1.818%
  Crude Oil ▲
38.88 1.57%
  Euro ▲
1.1319 0.24%
  DJIA ▲
17633.11 0.56%
 
Subscribe Now Sign In
The Wall Street Journal
日本 (Japan)
  • U.S.
  • Asia
  • Europe
  • India
  • América Latina
  • Brasil
  • 中国 (China)
  • 日本 (Japan)
2016年3月30日
Sections
My Journal
  • ホーム
  • 経済
  • マーケット
  • ビジネス
  • テクノロジー
  • 国際
  • 国内
  • オピニオン・社説
  • ライフ
  • バロンズ
  • Today's Paper
  • SHOW ALL SECTIONS HIDE ALL SECTIONS
    • 経済 Home
      • 金融政策ウォッチ
      • Heard on the Street
    • マーケット Home
      • マーケットデータ
    • テクノロジー Home
      • Digits
      • ガジェットレビュー
    • 国際 Home
      • 北米
      • 米大統領選特集
      • アジア・オセアニア
      • 欧州
      • 中東・アフリカ
      • China's World
      • China Real Time Report
    • 国内 Home
      • 編集長インタビュー
    • オピニオン・社説 Home
      • オピニオ ン
      • 社説
    • ライフ Home
      • キャリア
      • ヘルス
    • バロンズ Home
      • 日本市場
      • IT注目銘柄
      • インタビュー
      • コラム
    HIDE ALL SECTIONS
Aim higher, reach further.
Get the Wall Street Journal $12 for 12 weeks. Subscribe Now
Sign In
  • ホーム
  • 経済
    • 金融政策ウォッチ
    • Heard on the Street
  • マーケット
    • マーケットデータ
  • ビジネス
  • テクノロジー
    • Digits
    • ガジェットレビュー
  • 国際
    • 北米
    • 米大統領選特集
    • アジア・オセアニア
    • 欧州
    • 中東・アフリカ
    • China's World
    • China Real Time Report
  • 国内
    • 編集長インタビュー
  • オピニオン・社説
    • オピニオ ン
    • 社説
  • ライフ
    • キャリア
    • ヘルス
  • バロンズ
    • 日本市場
    • IT注目銘柄
    • インタビュー
    • コラム
Search
Subscribe Sign In

Puma Biotechnology Inc. PBYI (U.S.: NYSE)

View All companies
  • AT CLOSE 4:02 PM EDT 03/29/16
  • $27.92 USD
  • -7.45 -21.06%
  • Volume 4,162,096
  • AFTER HOURS 7:59 PM EDT 03/29/16
  • $28.00 0.08 0.29%
  • AFTER HOURS Vol 22,033
  • Volume 4,162,096
  • 65 Day Avg Vol 742,688
  • 1 Day Range 25.20 - 29.78
  • 52 Week Range 25.20 - 244.90 (03/29/16 - 04/15/15)
  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • YTD
  • 1 Y
  • 3 Y
  • $
  • %
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 28.25
  • Prior Close 35.37 (03/28/16)
  • 1 Day
  • PBYI -21.06%
  • DJIA 0.56%
  • S&P Mid Cap 400 1.77%
  • Health Care/Life Sciences -0.25%
  • Overview

News Puma Biotechnology Inc.PBYI

    • 17 hours ago
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 19 hours ago
    • Dow Jones Newswires
    Puma Biotechnology Cut to Sector Perform From Outperform by RBC
    • Dow Jones Newswires
    • 03/28/16
    • Dow Jones Newswires
    Puma Biotechnology to Delay New-Drug-Application Filing After FDA Talks
    • Dow Jones Newswires
    • 03/28/16
    • Press Release
    Puma Biotechnology Updates Timeline for Filing New Drug Application
    • Press Release
    • 03/18/16
    • Press Release
    Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016
    • Press Release
    • 03/02/16
    • Press Release
    Puma Biotechnology to Present at Cowen's Health Care Conference
    • Press Release
    • 02/29/16
    • Press Release
    Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results
    • Press Release
    • 02/17/16
    • Press Release
    Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
    • Press Release
    • 02/16/16
    • Press Release
    Puma Biotechnology Announces the Conclusion and Final Results of Eshelman's Consent Solicitation
    • Press Release
    • 02/11/16
    • Press Release
    Puma Biotechnology's ExteNET Phase III Study Published Online in The Lancet Oncology
    • Press Release
    • 02/03/16
    • Press Release
    Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference
    • Press Release
    • 01/08/16
    • Press Release
    Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman's Consent Solicitation
    • Press Release
    • 01/04/16
    • Press Release
    Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
    • Press Release
    • 05/30/15
    • Barron's
    Preview
    • Barron's
    • 05/15/15
    • MarketWatch.com
    15 biotech stocks to put on your watch list now
    • MarketWatch.com
    • 12/30/14
    • The Wall Street Journal
    Year of Highs and Lows for Hedge Funds
    • The Wall Street Journal
    • 10/04/14
    • Barron's
    A Poor Quarter for U.S. Equity Funds
    • Barron's
    • 07/26/14
    • Barron's
    Charting the Market
    • Barron's
    • 07/23/14
    • WSJ Blogs
    Puma Biotech's 300% Rally Proves Wall Street Wrong
    • WSJ Blogs
    • 07/23/14
    • MarketWatch.com
    Puma Biotech’s blast-off is not a typical short squeeze
    • MarketWatch.com
    • 07/23/14
    • WSJ Blogs
    Stocks to Watch: Whirlpool, PepsiCo, Dow Chemical
    • WSJ Blogs
    • 07/22/14
    • The Wall Street Journal
    Puma Shares Soar on Breast-Cancer Therapy Study Results
    • The Wall Street Journal
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    N/A
  • EPS (TTM)
    $-7.44
  • Market Cap
    $1.15 B
  • Shares Outstanding
    32.45 M
  • Public Float
    27.50 M
  • Yield
    PBYI has not issued dividends in more than 1 year.
  • Latest Dividend
    N/A
  • Ex-Dividend Date
    N/A
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (03/15/16)

  • Shares Sold Short
    5.28 M
  • Change from Last
    -6.88%
  • Percent of Float
    19.21%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    1.00
    Net Money Flow ($)
    -98,850

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors PBYI

Company Change P/E (TTM)
ARIA

Ariad Pharmaceuticals Inc.

+2.33% +0.14 -
ARRY

Array BioPharma Inc.

+2.46% +0.07 -
ONTY

Oncothyreon Inc.

+0.90% +0.01 -
GSK

GlaxoSmithKline PLC ADR

+1.74% +0.69 7.68
PFE

Pfizer Inc.

+0.91% +0.27 24.23
CERU

Cerulean Pharma Inc.

+1.17% +0.03 -
  • More information on PBYI
  • Competitor Data Provided By: capital cube

Profile PBYI

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial...

10880 Wilshire Boulevard
Los Angeles California 90024
United States

  • Email
  • Website
  • Map
  • Employees 156
    Sector Biotechnology
  • Sales or Revenue -
    Industry Health Care/Life Sciences
  • 1Y Sales Change -
    Fiscal Year Ends December 31 Download Reports
  • Alan H. Auerbach Chairman, President, CEO & Secretary
  • Charles R. Eyler Treasurer & Senior VP-Finance & Administration
  • Frank E. Zavrl Director
  • Jay M. Moyes Independent Director
  • More

Research & Ratings Puma Biotechnology Inc.PBYI

Per-Share Earnings, Actuals and Estimates

  • Quarterly
  • Annual
PBYI will report FY 2015 earnings on 03/28/2016 PBYI will report Q4 earnings on 03/28/2016
Actual Analyst Range Consensus
2 1 0 -1 -2
Actual -1.57
-1.33
Actual -1.66
-1.39
Actual -2.01
-1.62
Actual -1.87
-1.76
-1.87
-1.99
Q42014 Q12015 Q2 Q3 Q4 Q12016
5 0 -5 -10
Actual -7.45
-4.56
-7.42
-7.87
-7.43
FY 2014 FY 2015 FY 2016 FY 2017
Q4 2015 Estimate Trends
Current: $-1.87
1 month ago: $-1.95
3 months ago: $-1.85
Q1 2016 Estimate Trends
Current: $-1.99
1 month ago: $-2.14
3 months ago: $-2.01
FY 2015 Estimate Trends
Current: $-7.42
1 month ago: $-7.50
3 months ago: $-7.39
FY 2016 Estimate Trends
Current: $-7.87
1 month ago: $-7.79
3 months ago: $-7.59
  • More

Financials Puma Biotechnology Inc.PBYI

  • Quarterly
  • Annual

Net Income

0
0 -20M -40M -60M -80M
Dec 2014 Mar 2015 Jun 2015 Sep 2015 Dec 2015
0
0 -60M -120M -180M -240M
'11 '12 '13 '14 '15
Dec 2015 5-quarter trend
Net Income Growth -29.89%
Sales or Revenue -
Sales or Revenue Growth -
EBITDA -61.89 M
2015 5-year trend
Net Income Growth -68.55%
Sales or Revenue -
Sales or Revenue Growth -
EBITDA -239.50 M
  • More
  • Overview

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement
  • Wall Street Journal
  • 日本 (Japan)
    • U.S.
    • Asia
    • Europe
    • India
    • América Latina
    • Brasil
    • 中国 (China)
    • 日本 (Japan)
  • Subscribe NowSign In

  • WSJ Membership Benefits
  • Download WSJ Apps
  • Customer Center
  • Legal Policies
  • Subscribe
  • Sign In
  • TOP«
  • Customer Service

  • Customer Center
  • Contact Us
  • About Us
  • Ads

  • About Ads
  • Tools & Features

  • iPhone App
  • iPad App
  • Android App
  • Newsletter
  • About Japanese Blog Parts
  • More

  • About Houjin Subscribing
  • Events
  • Maintenence Info
  • Jobs at WSJ
  • Site Map
    • Facebook
    • Twitter
    • Google+
    • YouTube
    • Podcasts
    • GooglePlay
    • AppStore
  • Dow Jones Products
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Private Markets
  • realtor.com
  • Risk & Compliance
  • WSJ Conference
  • WSJ Pro Central Banking
  • WSJ Video
  • WSJ Wine
  • BallBall
  • Privacy Policy
  • Cookie Policy
  • Tokusyo
  • Data Policy
  • Subscriber Agreement & Terms of Use
  • Copyright ©2016 Dow Jones & Company, Inc. All Rights Reserved.